| abstract |
The present invention provides immune cells and vaccines targeting coagulation factor XI, and uses for the treatment of metabolic syndrome. Specifically, the present invention provides a recombinant protein carrying a coagulation factor XI structural element and a carrier protein, wherein a preferred example is a recombinant protein formed by connecting the catalytic domain of human coagulation factor XI to the C-terminus of the diphtheria toxin translocation domain. The recombinant protein antigen of the present invention can be used as a component of a vaccine preparation to prepare immune cells targeting coagulation factor XI in vitro, and then infuse into the body, or directly immunize in vivo, effectively stimulate the immune response against coagulation factor XI, and has the advantages of losing weight, improving glucose tolerance, reducing Therapeutic effect of blood total cholesterol concentration and blood alanine aminotransferase activity. Compared with monoclonal antibody drugs and small molecule drugs, immune cells and vaccines have many advantages, including low administration frequency, low dosage, and long duration of therapeutic effect, so patients have better medication convenience and compliance. Sex and being able to obtain greater health benefits. |